Literature DB >> 31356731

Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: Results from an American nationally representative study.

Elena Bilevicius1,2, Jordana L Sommer1,2, Gordon J G Asmundson3, Renée El-Gabalawy1,2,4.   

Abstract

BACKGROUND: Cannabis can be prescribed for posttraumatic stress disorder (PTSD) and chronic pain, and comorbid cannabis use disorder (CUD) can occur in both conditions. Research demonstrates that PTSD and chronic pain commonly co-occur.
METHODS: Data were acquired from the National Epidemiologic Survey on Alcohol and Related Conditions-III (N = 36,309). Past-year CUD and PTSD were assessed using the Alcohol Use Disorder and Associated Disabilities Interview Schedule-5. Past-year physician-confirmed chronic pain was self-reported and classified as musculoskeletal (e.g., arthritis), digestive (e.g., pancreatitis), and nerve (e.g., reflex sympathetic dystrophy) pain. Weighted cross-tabulations assessed sociodemographic, psychiatric, and chronic pain condition variables among those with PTSD versus no PTSD, among the entire sample and among those with CUD and chronic pain. Multiple logistic regressions examined the relationship between PTSD and chronic pain with CUD. CUD characteristics were also evaluated across PTSD and chronic pain groups.
RESULTS: Rates of CUD were elevated in PTSD (9.4%) compared to those without (2.2%). The odds of CUD were greater for PTSD+digestive pain, PTSD+nerve pain, and PTSD+any chronic pain compared to having neither PTSD nor chronic pain (odds ratio range: 1.88-2.32). PTSD with and without comorbid chronic pain was associated with overall elevated rates of adverse CUD characteristics, including earlier age of onset, greater usage, and greater CUD severity.
CONCLUSIONS: PTSD with and without chronic pain is associated with elevated rates and severity of CUD. These results may have implications for prescribing practices and understanding individuals at risk for developing CUD.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NESARC-III; cannabis use disorder; chronic pain; epidemiology; posttraumatic stress disorder

Mesh:

Year:  2019        PMID: 31356731     DOI: 10.1002/da.22947

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  3 in total

1.  Gender Differences in Diagnostic Remission of Posttraumatic Stress Disorder (PTSD): Proportions and Correlates of Remission in a Nationally Representative U.S. Sample.

Authors:  Elina A Stefanovics; Taeho G Rhee; Robert A Rosenheck
Journal:  Psychiatr Q       Date:  2022-03-30

2.  A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.

Authors:  Sebastian Jugl; Aimalohi Okpeku; Brianna Costales; Earl J Morris; Golnoosh Alipour-Haris; Juan M Hincapie-Castillo; Nichole E Stetten; Ruba Sajdeya; Shailina Keshwani; Verlin Joseph; Yahan Zhang; Yun Shen; Lauren Adkins; Almut G Winterstein; Amie Goodin
Journal:  Med Cannabis Cannabinoids       Date:  2021-02-25

3.  Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada.

Authors:  Shaina P Cahill; Stephanie E Lunn; Patrick Diaz; Jonathan E Page
Journal:  Front Public Health       Date:  2021-05-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.